Brian Culley Purchases 15,000 Shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) CEO Brian Culley purchased 15,000 shares of the business’s stock in a transaction dated Thursday, March 12th. The stock was purchased at an average price of $1.62 per share, for a total transaction of $24,300.00. Following the completion of the acquisition, the chief executive officer owned 255,516 shares of the company’s stock, valued at approximately $413,935.92. This represents a 6.24% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Lineage Cell Therapeutics Trading Down 5.7%

Shares of LCTX stock traded down $0.10 on Thursday, hitting $1.59. 1,433,015 shares of the stock were exchanged, compared to its average volume of 1,151,963. The firm has a market capitalization of $394.81 million, a P/E ratio of -5.66 and a beta of 1.74. Lineage Cell Therapeutics, Inc. has a fifty-two week low of $0.37 and a fifty-two week high of $2.09. The business has a 50-day moving average of $1.73 and a 200 day moving average of $1.66.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last announced its earnings results on Thursday, March 5th. The company reported $0.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.07. Lineage Cell Therapeutics had a negative return on equity of 76.13% and a negative net margin of 436.47%.The business had revenue of $6.61 million for the quarter, compared to analyst estimates of $1.96 million. As a group, research analysts forecast that Lineage Cell Therapeutics, Inc. will post -0.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on LCTX. D. Boral Capital increased their target price on shares of Lineage Cell Therapeutics from $2.00 to $3.00 and gave the stock a “buy” rating in a report on Friday, March 6th. HC Wainwright reissued a “buy” rating on shares of Lineage Cell Therapeutics in a research report on Friday, March 6th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $5.00.

Institutional Trading of Lineage Cell Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Defender Capital LLC. bought a new position in shares of Lineage Cell Therapeutics in the 4th quarter valued at about $11,405,000. Marshall Wace LLP acquired a new stake in Lineage Cell Therapeutics in the 4th quarter valued at about $2,275,000. Goldman Sachs Group Inc. lifted its stake in Lineage Cell Therapeutics by 894.5% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,438,746 shares of the company’s stock valued at $2,403,000 after purchasing an additional 1,294,070 shares during the last quarter. Jane Street Group LLC grew its holdings in Lineage Cell Therapeutics by 494.7% during the fourth quarter. Jane Street Group LLC now owns 1,004,794 shares of the company’s stock worth $1,678,000 after purchasing an additional 835,831 shares during the period. Finally, Vanguard Group Inc. increased its position in Lineage Cell Therapeutics by 6.2% during the third quarter. Vanguard Group Inc. now owns 9,006,930 shares of the company’s stock worth $15,222,000 after buying an additional 524,057 shares during the last quarter. 62.47% of the stock is owned by institutional investors.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.